NTHI (NeOnc Technologies Holdings) ROC %: -621.50% (As of Mar. 2026)


NTHI NeOnc Technologies Holdings Inc NTHI
7 GF Score
Price $4.41
! 1 Warning Sign
View Full Analysis

What is NeOnc Technologies Holdings ROC %?

NeOnc Technologies Holdings NTHI -0.90% 7 ROC % is -621.50% as of Mar. 2026. GuruFocus rates NTHI with a GF Score™ of 7/100. The stock has 1 warning sign investors should review.

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. NeOnc Technologies Holdings's annualized return on capital (ROC %) for the quarter that ended in Mar. 2026 was -621.50%.

As of today (2026-07-03), NeOnc Technologies Holdings's WACC % is 12.92%. NeOnc Technologies Holdings's ROC % is -906.66% (calculated using TTM income statement data). NeOnc Technologies Holdings earns returns that do not match up to its cost of capital. It will destroy value as it grows.


NeOnc Technologies Holdings  (NAS:NTHI) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, NeOnc Technologies Holdings's WACC % is 12.92%. NeOnc Technologies Holdings's ROC % is -906.66% (calculated using TTM income statement data). NeOnc Technologies Holdings earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


NeOnc Technologies Holdings ROC % Related Terms


NeOnc Technologies Holdings ROC % Historical Data

* Premium members only.

The historical data trend for NeOnc Technologies Holdings's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NeOnc Technologies Holdings ROC % Chart

NeOnc Technologies Holdings Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
ROC %
-154.92 -184.65 -187.04 -147.61 -1,199.98

NeOnc Technologies Holdings Quarterly Data
Dec21 Sep22 Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7,277.10 -1,434.17 -710.92 -786.49 -621.50
NTHI
7GF Score
NeOnc Technologies Holdings Inc NTHI
ROC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NeOnc Technologies Holdings ROC % Calculation

NeOnc Technologies Holdings's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2025 is calculated as:

ROC % (A: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2024 ) + Invested Capital (A: Dec. 2025 ))/ count )
=-58.169 * ( 1 - 0% )/( (1.981 + 7.714)/ 2 )
=-58.169/4.8475
=-1,199.98 %

where

NeOnc Technologies Holdings's annualized Return on Capital (ROC %) for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-28.036 * ( 1 - 0% )/( (7.714 + 1.308)/ 2 )
=-28.036/4.511
=-621.50 %

where

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data. The tax rate is limited to between 0% and 100%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROC % →
What does a ROC % of -621.50% mean?
NeOnc Technologies Holdings (NTHI) has a ROC % of -621.50% as of Mar. 2026. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on NeOnc Technologies Holdings and its competitors.
Is NeOnc Technologies Holdings' ROC % too high?
NeOnc Technologies Holdings' current ROC % is -621.50%. Overall, NeOnc Technologies Holdings has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does NeOnc Technologies Holdings' ROC % compare to GUTS and PEPG?
NeOnc Technologies Holdings' ROC % of -621.50% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC % for a Biotechnology company?
A good ROC % depends on the Biotechnology industry context. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC % mean?
A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on NeOnc Technologies Holdings and its competitors. NeOnc Technologies Holdings's current ROC % is -621.50%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeOnc Technologies Holdings stock overvalued right now?
NeOnc Technologies Holdings (NTHI) has a current ROC % of -621.50%. The current ROC % is -621.50%. NeOnc Technologies Holdings' overall GF Score™ is 7/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC % calculated?
ROC % is calculated from a company's financial statements. For NeOnc Technologies Holdings (NTHI), the current ROC % is -621.50% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NeOnc Technologies Holdings Business Description

Address 23975 Park Sorrento, Suite 205, Calabasas, CA, USA, 91302
NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.
7GF Score

Get the complete analysis for NTHI

ROC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.41
Price